Clinical trial · no report yet · Phase 3
TROPION-Lung07
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- NCT05555732 ↗
- Active, not recruiting
- Daiichi Sankyo
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 14 | |
| Podcasts | 9 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin
- Arms
- Dato-DXd + Pembrolizumab + Platinum Chemotherapy · Experimental
- Dato-DXd + Pembrolizumab · Experimental
- Pembrolizumab + Pemetrexed + Platinum Chemotherapy · Active comparator
- Enrollment
- 1,170 (estimated)
- Primary outcomes
- Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants
- Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants who are TROP2 NMR positive
- Overall Survival in All Randomized Participants
- Overall Survival in All Randomized Participants who are TROP2 NMR positive
- Sponsor
- Daiichi Sankyo with AstraZeneca, Merck Sharp & Dohme LLC
- Start
- Jan 11, 2023
- Primary completion
- May 11, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05555732 · updated Jun 23, 2026
Publications
linked from the registry- Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, Danchaivijitr P, Han JY, Sun JM, Sugawara S, Pan E, Ren N, Chen A, Rajagopalan R, Lisberg AE. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab +/- platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol. 2024;20(37):2927-2936. doi: 10.1080/14796694.2024.2409621. Epub 2024 Oct 29. PubMed 39469838